News & Updates
Filter by Specialty:
Add-on amantadine lessens “off” episodes in Parkinson’s disease
A delayed release/extended release (DR/ER) formulation of amantadine can help reduce breakthrough symptoms in Parkinson’s disease patients when the effect of levodopa therapy wears off, as shown in a recent study.
Add-on amantadine lessens “off” episodes in Parkinson’s disease
06 Apr 2022
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
06 Apr 2022
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
06 Apr 2022
SGLT2i lowers serum urate regardless of diabetes status
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) can keep serum urate levels low in patients with and without diabetes, according to a recent Singapore study.
SGLT2i lowers serum urate regardless of diabetes status
06 Apr 2022
Continued anti-VEGF use after disease control does not prevent nAMD recurrence
In patients with neovascular age-related macular degeneration (nAMD) who achieve functional and morphological disease stability, continuing treatment with antivascular endothelial growth factors (anti-VEGF) does not substantially reduce the risk of recurrence, reports a recent study.
Continued anti-VEGF use after disease control does not prevent nAMD recurrence
06 Apr 2022
Insulin pump, CGM use linked to better glucose control during pregnancy
The use of either an insulin pump or a continuous glucose monitoring (CGM) device among pregnant women with type 1 diabetes leads to improved glycaemic control, although pump use appears to be linked to higher birth weight measures, a study has found.
